NCT03157167 2025-03-05An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)Navidea BiopharmaceuticalsPhase 1 Completed15 enrolled 12 charts